Coherus BioSciences, Inc. Financials

Market Capitalization $93.9 Million as of July 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-0.90
Forward PE	56.75
Price to Sales TTM	$1.00
Price to Book MRQ	$
Enterprise to Revenue	2.41
Enterprise to EBITDA	-3.27

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	-92.48%
Operating Margin	-98.78%
Return on Assets TTM	-21.75%
Return on Equity TTM	122.99%

Income Statement

Revenue TTM	$257,244,000
Revenue per Share TTM	$2.73
Quarterly Revenue Growth	101.80%
Gross Profit TTM	$98,252,000
EBITDA	$-189,408,000
Net Income to Common TTM	$-237,892,000
Diluted EPS TTM	$-2.53
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$117,748,000
Total Cash per Share MRQ	$1.05
Total Debt MRQ	$
Total Debt to Equity MRQ	-2.49
Current Ratio MRQ	1.43
Book Value per Share MRQ	$-1.72

Cash Flow

Operating Cash Flow TTM	$-174,884,000
Levered Free Cash Flow TTM	$-70,097,128

CHRS Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	113,498,000
Float Shares	103,870,909
Avg 10 Volume	1,249,953
Avg 30 Volume	None
Shares Short	21,533,726
Short Ratio	8.97
Short % of Shares	22.20%
% Held by Insiders	1.41%
% Held by Institutions	76.76%

Stock Price Summary

Beta	0.51
Fifty Two Week Low	$1.43
Fifty Two Week High	$8.22
Fifty Two Week Change	-258.59%
Day 50 MA	$2.28
Day 200 MA	$3.07

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date